Indeed, further molecular characterization showed that PH003 harbors a KRAS mutation in codon 12, p.Gly12Asp, which was previously described in lung [43] and colon cancers [44], and is associated with decreased efficacy of EGFR inhibitors afatinib and gefitinib [45]. The gene discussed is EGFR; the disease is colonic neoplasm.